

Figure S3




Figure S3. Molecular expression differences between brain metastases and primary tumor. **A.** Comparison of immune checkpoint molecule expression (PDCD1, CTLA4, and TIGIT) between PT and paired BM; **B.** Comparison of immune cell markers expression (CD3E, CD4 and CD8A) between PT and paired BM; **C.** The correlation between PD-L1 expression and CD4/CD8A expression in primary tumor, respectively; **D.** The correlation between PD-L1 expression and CD4/CD8A expression in primary tumor, respectively; **E.** Comparison of IFN-gamma signature between PT and paired BM.

Supplementary Materials

[Supplementary Materials](#) ↩

[Supplementary Figure](#) ↩

[Figure S1.](#) Flowchart of the study design. ↩

[Figure S2.](#) GSEA based on hallmark gene sets between brain metastases and primary LUAD. **A.** GSEA of brain metastases using hallmark gene sets; **B.** GSEA of primary LUAD using hallmark gene sets. ↩

Figure S3. Molecular expression differences between brain metastases and primary tumor. **A.** Comparison of immune checkpoint molecule expression (PDCD1, CTLA4, and TIGIT) between PT and paired BM; **B.** Comparison of immune cell markers expression (CD3E, CD4 and CD8A) between PT and paired BM; **C.** The correlation between PD-L1 expression and CD4/CD8A expression in primary tumor, respectively; **D.** The correlation between PD-L1 expression and CD4/CD8A expression in primary tumor, respectively; **E.** Comparison of IFN-gamma signature between PT and paired BM. ↩

Figure S4. The infiltration levels of immune cell between BM (n = 6) and paired PT (n = 6) were compared using MCPYCOUNTER and CIBERSORT. **A.** Comparison of six immune cells infiltration (B cell, CTL, Myeloid DC, Monocyte, NK cell and T cell) between PT and paired BM using MCPYCOUNTER; **B.** Comparison of three immune cells infiltration (CD8+ T cell, Plasma cell and NK resting cell) between PT and paired BM using CIBERSORT. ↩

The correct version ↩

Figure S3. Molecular expression differences between brain metastases and primary tumor. **A.** Comparison of immune cell markers expression (CD3E, CD4 and CD8A) between PT and paired BM; **B.** Comparison of immune checkpoint molecule expression (PDCD1, CTLA4, and TIGIT) between PT and paired BM; ↩